(Q36794811)

16 August 2017

1 reference

title

Signal-transduction inhibitors in renal cell carcinoma (English)

1 reference

16 August 2017

Nicholas J Vogelzang

1

1 reference

PubMed ID

17441926

16 August 2017

Cora N Sternberg

series ordinal

2

1 reference

16 August 2017

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

99

1 reference

16 August 2017

5 Pt B

1 reference

16 August 2017

1289-1295

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

16 August 2017

1 reference

What's new in the treatment of metastatic kidney cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Bevacizumab and erlotinib show promise for kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Targeted agents for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06833.X

10.1111/J.1464-410X.2007.06833.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17441926